Upstream Bio, Inc. (UPB)
$6.69-$0.10 (-1.47%) Today
Everett Rand Sutherland - Officer
Aaron Deykin - Officer
Michael Gray - OfficerAaron Deykin - OfficerEverett Rand Sutherland - OfficerUpstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. Verekitug has advanced into three separate world-wide, placebo-controlled, randomized Phase 2 clinical trials, two completed in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, and one ongoing in chronic obstructive pulmonary disease (COPD).
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 5,020 | $31K |
| Grant or award | 6 | 102,576 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
32 Form 4 filings on record, the earliest from Oct 15, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael Gray - Officer | Open-market sale | Common Stock | 853 | $6.10 | $5K | |
| Everett Rand Sutherland - Officer | Open-market sale | Common Stock | 2,095 | $6.10 | $13K | |
| Adam Houghton - Officer | Open-market sale | Common Stock | 700 | $6.10 | $4K | |
| Aaron Deykin - Officer | Open-market sale | Common Stock | 895 | $6.10 | $5K | |
| Allison Ambrose - Officer | Open-market sale | Common Stock | 477 | $6.10 | $3K | |
| Marcella K. Ruddy | Grant or award | Stock Option (Right to Buy) | 17,096 | $0.00 | - | |
| Ronald C. Renaud Jr. | Grant or award | Stock Option (Right to Buy) | 17,096 | $0.00 | - | |
| Harold Edward Fleming | Grant or award | Stock Option (Right to Buy) | 17,096 | $0.00 | - | |
 Daniella Beckman | Grant or award | Stock Option (Right to Buy) | 17,096 | $0.00 | - | |
| Liam Ratcliffe | Grant or award | Stock Option (Right to Buy) | 17,096 | $0.00 | - | |
| Erez Chimovits | Grant or award | Stock Option (Right to Buy) | 17,096 | $0.00 | - | |
| Michael Gray - Officer | Open-market sale | Common Stock | 852 | $9.29 | $8K | |
| Aaron Deykin - Officer | Open-market sale | Common Stock | 894 | $9.29 | $8K | |
| Everett Rand Sutherland - Officer | Open-market sale | Common Stock | 2,093 | $9.29 | $19K | |
| Allison Ambrose - Officer | Open-market sale | Common Stock | 475 | $9.29 | $4K | |
| Adam Houghton - Officer | Open-market sale | Common Stock | 699 | $9.29 | $6K | |
| Michael Gray - Officer | Grant or award | Common Stock | 30,500 | $0.00 | - | |
| Michael Gray - Officer | Grant or award | Stock Option (Right to Buy) | 91,500 | $0.00 | - | |
| Aaron Deykin - Officer | Grant or award | Common Stock | 32,000 | $0.00 | - | |
| Aaron Deykin - Officer | Grant or award | Stock Option (Right to Buy) | 96,000 | $0.00 | - | |
| Allison Ambrose - Officer | Grant or award | Common Stock | 17,000 | $0.00 | - | |
| Allison Ambrose - Officer | Grant or award | Stock Option (Right to Buy) | 51,000 | $0.00 | - | |
| Adam Houghton - Officer | Grant or award | Common Stock | 25,000 | $0.00 | - | |
| Adam Houghton - Officer | Grant or award | Stock Option (Right to Buy) | 75,000 | $0.00 | - | |
| Everett Rand Sutherland - Officer | Grant or award | Common Stock | 75,000 | $0.00 | - | |
| Everett Rand Sutherland - Officer | Grant or award | Stock Option (Right to Buy) | 225,000 | $0.00 | - | |
| Allison Ambrose - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | $0.00 | - | |
| Erez Chimovits - Director | Other | Common Stock | 721,956 | - | - | |
| Erez Chimovits - Director | Open-market purchase | Common Stock | 165,000 | $17.00 | $2.81M | |
| Erez Chimovits - Director | Other | Common Stock | 2,887,833 | - | - | |
| Erez Chimovits - Director | Open-market purchase | Common Stock | 660,000 | $17.00 | $11.22M | |
| Erez Chimovits - Director | Other | Series A redeemable convertible preferred stock | 524,500 | - | - | |
| Erez Chimovits - Director | Other | Series A redeemable convertible preferred stock | 2,098,000 | - | - | |
| Erez Chimovits - Director | Other | Series B redeemable convertible preferred stock | 197,456 | - | - | |
| Erez Chimovits - Director | Other | Series B redeemable convertible preferred stock | 789,833 | - | - | |
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 721,956 | - | - | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Stock | 165,000 | $17.00 | $2.81M | |
| ORBIMED ADVISORS LLC - Director | Other | Common Stock | 2,887,833 | - | - | |
| ORBIMED ADVISORS LLC - Director | Open-market purchase | Common Stock | 660,000 | $17.00 | $11.22M | |
| ORBIMED ADVISORS LLC - Director | Other | Series A redeemable convertible preferred stock | 524,500 | - | - | |
| ORBIMED ADVISORS LLC - Director | Other | Series A redeemable convertible preferred stock | 2,098,000 | - | - | |
| ORBIMED ADVISORS LLC - Director | Other | Series B redeemable convertible preferred stock | 197,456 | - | - | |
| ORBIMED ADVISORS LLC - Director | Other | Series B redeemable convertible preferred stock | 789,833 | - | - | |
| AI Upstream LLC | Open-market purchase | Common Stock | 1,175,000 | $17.00 | $19.98M | |
| AI Upstream LLC | Other | Common Stock | 3,147,000 | - | - | |
| AI Upstream LLC | Other | Common Stock | 1,172,410 | - | - | |
| AI Upstream LLC | Other | Series A Convertible Preferred Stock | 3,147,000 | - | - | |
| AI Upstream LLC | Other | Series B Convertible Preferred Stock | 1,172,410 | - | - | |
| Erez Chimovits | Grant or award | Stock Option (Right to Buy) | 17,096 | $0.00 | - | |
| Ronald C. Renaud Jr. | Grant or award | Stock Option (Right to Buy) | 17,096 | $0.00 | - | |
| Daniella Beckman | Grant or award | Stock Option (Right to Buy) | 34,681 | $0.00 | - | |
| Liam Ratcliffe | Grant or award | Stock Option (Right to Buy) | 17,096 | $0.00 | - | |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | Other | Common Stock | 894,733 | - | - | |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | Other | Series B redeemable convertible preferred stock | 852,940 | $0.00 | - |
Upstream Bio, Inc. (UPB) had 11 insider filings in the last 90 days, with the most recent on 2026-06-17. The full record for UPB runs to 32 Form 4 filings, the earliest from 2024-10-15. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of UPB were filed in the last 90 days. 5 purchases are on record for this company.
5 insider sales of UPB were filed in the last 90 days, totaling $31K.
This page tracks UPB Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add UPB to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
